CAMBRIDGE, UK – September 27, 2025 – Upfront Diagnostics, today announced it has been honoured with the Innovation of the Year award at the 2025 Cambridge Independent Business Awards. The highly coveted award recognises the company’s groundbreaking advancements in diagnostic technology and its potential to significantly impact patient care globally.
The award was presented at a ceremony celebrating the region’s most successful and innovative businesses, acknowledging Upfront Diagnostics’ dedication to developing rapid, accurate, and accessible diagnostic tools. The recognition underscores the company’s success in bringing a disruptive technology to market that addresses critical unmet needs in the healthcare sector.
“We are deeply honoured and thrilled to receive the Innovation of the Year award from the Cambridge Independent,” said Gonzalo Ladreda, CEO of Upfront Diagnostics. “This accolade is a testament to the hard work, dedication, and ingenuity of our entire team. It validates our mission to put better, faster diagnostics Upfront—where they can make the biggest difference in treatment outcomes and patient lives. Cambridge is a hub for world-class innovation, and to be recognised here at our home is truly special.”
The Cambridge Independent Business Awards celebrate organisations driving economic growth and setting new standards for excellence. Upfront Diagnostics was selected by the judging panel for the novelty and transformative potential of its core technology. The company intends to use this momentum to accelerate the deployment of its innovative platform, ensuring its benefits reach healthcare providers and patients worldwide.
About UpFront Diagnostics
Founded in Cambridge, UK, in 2017, UpFront Diagnostics is a MedTech company pioneering point-of-care diagnostics for critical, time-sensitive conditions. The company’s lead product, LVOne, is designed to revolutionise emergency stroke care by providing immediate, actionable diagnostic information. UpFront Diagnostics is committed to transforming patient outcomes by solving the current triage gap in stroke pathways.
